Evidence map›Paper›PMID 41521170›Full record

ArticleScientific reports2026

Affinity of drug candidates binding to SARS-CoV-2 PLpro assessed using a generalized-ensemble method.

Masashi Muramoto, Simon Hikiri, Suzuka Saito, Qilin Xie, Kota Kasahara, Junichi Higo, Takuya Takahashi

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Masashi MuramotoGraduate School of Life Sciences, Ritsumeikan University, 1-1-1 Noji-higashi, Kusatsu, Shiga, 525-8577, Japan.
Simon HikiriCollege of Life Sciences, Ritsumeikan University, 1-1-1 Noji-higashi, Kusatsu, Shiga, 525-8577, Japan.
Suzuka SaitoGraduate School of Life Sciences, Ritsumeikan University, 1-1-1 Noji-higashi, Kusatsu, Shiga, 525-8577, Japan.
Qilin XieGraduate School of Life Sciences, Ritsumeikan University, 1-1-1 Noji-higashi, Kusatsu, Shiga, 525-8577, Japan.
Kota KasaharaCollege of Life Sciences, Ritsumeikan University, 1-1-1 Noji-higashi, Kusatsu, Shiga, 525-8577, Japan.
Junichi HigoGraduate School of Information Science, University of Hyogo, 7-1-28 Minatojima Minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
Takuya TakahashiCollege of Life Sciences, Ritsumeikan University, 1-1-1 Noji-higashi, Kusatsu, Shiga, 525-8577, Japan. tkhs@sk.ritsumei.ac.jp.

Funding

HPCI System Research Project hp220002, hp220015, hp220022, hp230003, hp230011, hp230013, hp230109, hp240032, hp240167, hp250017, and hp250061JSPS KAKENHI 21K06052
6 · The paper itself

Abstract

To establish a procedure for screening compounds that inhibit ligand-receptor binding, we employed a multidimensional virtual-system coupled molecular dynamics (mD-VcMD), a generalized ensemble method recently developed by our group. In this approach, each compound is initially placed far from the receptor. Both receptor and compound were fully flexible in explicit solvent during sampling. The mD-VcMD generated a free-energy landscape of the compound-receptor interactions, in which a probability of existence was assigned to each sampled conformation. We examined four compounds that bind to the papain-like protease (PLpro) of SARS-CoV-2. The resultant free-energy landscapes were funnel-like for all compounds. The probabilities assigned to the free-energy basins correlated well with the measured dissociation constants. Furthermore, structural clustering revealed two types of binding modes within the free-energy basin. The probabilities assigned to the binding modes correlated well with the measured enzyme inhibitory activity. These results suggest that the proposed procedure is effective for selecting candidate inhibitors among the examined compounds.

Indexed as

Antiviral AgentsBetacoronavirusCoronavirus Papain-Like ProteasesCysteine EndopeptidasesSARS-CoV-2Binding SitesHumansLigandsMolecular Dynamics SimulationProtein BindingThermodynamicsAntiviral AgentsCoronavirus Papain-Like ProteasesCysteine EndopeptidasesLigandspapain-like protease, SARS-CoV-2Binding affinityDrug discoveryGeneralized ensemblemD-VcMDMolecular bindingSARS-CoV-2 PLpro

Identifiers

PMID41521170
PMCPMC12859015

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.